Alaunos Therapeutics, Inc. - רווח נקי למניה ב-12 החודשים האחרונים TCRT

Alaunos Therapeutics (TCRT) is developing cutting-edge TCR-T therapies to combat solid tumors, leveraging partnerships with medical centers to drive FCF growth. High costs associated with sterile synthesis and patents create a steep barrier to entry, while the environmental footprint remains minimal. The current TTM EPS annual growth rate illustrates financial stability, where 21.40 serves as the baseline parameter value.
פילוחי מדדים פיננסיים ומדדי שוק עבור Alaunos Therapeutics, Inc. (TCRT)

This indicator measures the annual growth of net income per share, allowing for an assessment of capital scaling rates. For Alaunos Therapeutics (TCRT), the EPS YoY TTM growth efficiency metric reflects financial stability during the development of TCR-T drugs. The upward trend here confirms the successful commercialization of the Sleeping Beauty platform. Sharp spikes in values often create noise that masks long-term trends. While steady growth reduces investment risks, excessive acceleration may signal imminent market saturation.